Keros Therapeutics Inc KROS.OQ KROS.O is expected to show a rise in quarterly revenue when it reports results on November 4 (estimated) for the period ending September 30 2025
The Lexington Massachusetts-based company is expected to report a 879.4% increase in revenue to $3.8 million from $388 thousand a year ago, according to the mean estimate from 10 analysts, based on LSEG data.
LSEG's mean analyst estimate for Keros Therapeutics Inc is for a loss of $1.05 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Keros Therapeutics Inc is $22.50, about 33.2% above its last closing price of $15.03
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -1.10 | -1.13 | -0.76 | Beat | 32.9 |
Mar. 31 2025 | -0.15 | -0.24 | 3.62 | Beat | 1,589.7 |
Dec. 31 2024 | -0.73 | -0.98 | -1.14 | Missed | -16 |
Sep. 30 2024 | -1.26 | -1.28 | -1.41 | Missed | -10.2 |
Jun. 30 2024 | -1.23 | -1.23 | -1.25 | Missed | -1.5 |
Mar. 31 2024 | -1.30 | -1.35 | -1.21 | Beat | 10.2 |
Dec. 31 2023 | -1.35 | -1.37 | -1.34 | Beat | 2.5 |
Sep. 30 2023 | -1.34 | -1.35 | -1.33 | Beat | 1.3 |
This summary was machine generated October 31 at 23:35 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments